Last updated on March 2019

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies


Brief description of study

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Clinical Study Identifier: NCT00781612

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: BO25430 ...

Instituto Nacional de Cancer
D.f., Mexico
2.22miles
  Connect »

Reference Study ID Number: BO25430 ...

Consultorio de Medicina Especializada
Mexico, Mexico
5.11miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.